Clinical trials: Malignant Primary Gliomas, open to volunteers
Glioblastoma, Brain Tumor, Primary
Research on the Safety and Efficacy of Intraoperative Radiation Therapy in Malignant Cerebral Tumor
According to the latest national cancer statistics released by the National Cancer Center in February 2022, intracranial tumors account for about 60%-70% of the more than 3.5 million cancer patients, and the morbidity and…
- Conditions
- Glioblastoma, Brain Tumor, Primary, Brain Tumor - Metastatic
- Trial name
- NCT06929819
- Testing
- Intraoperative Radiation Therapy in Malignant Cerebral Tumor
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Neoplasms, Brain, Glioblastoma Multiforme
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor.
- Conditions
- Neoplasms, Brain, Glioblastoma Multiforme, Glioblastoma of Cerebellum, Neoplasms
- Trial name
- NCT03911388
- Testing
- G207
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Amyloidosis, Basal Cell Carcinoma
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and…
- Conditions
- Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma, Bladder Carcinoma
- Trial name
- NCT07285044
- Testing
- Cancer Therapeutic Procedure, Questionnaire Administration
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Mayo Clinic
Glioma, Brain Tumor
Non-invasive Glioma Characterization Through Molecular Imaging
MRI-based sequences can provide non-invasive quantification of intratumoral 2-hydroxyglutarate (2HG) distribution and tumor cellularity in human gliomas and help guide the development of novel glioma therapies.
- Conditions
- Glioma, Brain Tumor, Primary Brain Tumor, Malignant Glioma
- Trial name
- NCT03684109
- Testing
- 3T MRI Scanner
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Miami
Primary Malignant Brain Tumor, Glioblastoma (GBM)
FearLess in NeuroOncology
The overarching goal of this project is to assess the feasibility, acceptability, and appropriateness of recruitment methods, target population, and a waitlist design to finalize the protocol of FearLess in primary malignant…
- Conditions
- Primary Malignant Brain Tumor, Glioblastoma (GBM), Astrocytoma, Oligodendroglioma
- Trial name
- NCT06989086
- Testing
- Fearless in Neuro-Oncology
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Virginia Commonwealth University
Recurrent Diffuse Hemispheric Glioma, H3 G34-Mutant, Recurrent Malignant Brain Neoplasm
Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors
This phase I trial tests the safety, side effects and best dose of AdV-HSV1-TK and AdV-Flt3L in combination with valacyclovir for the treatment of patients with primary cancerous (malignant) brain tumors that can be removed by…
- Conditions
- Recurrent Diffuse Hemispheric Glioma, H3 G34-Mutant, Recurrent Malignant Brain Neoplasm, Resectable Brain Neoplasm
- Trial name
- NCT06914479
- Testing
- Ad-hCMV-Flt3L, Ad-hCMV-TK, Biospecimen Collection
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Michigan Rogel Cancer Center
Diffuse Midline Glioma (DMG), Glioblastoma
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
This phase I trial studies the effects and best dose of ONC206 alone or in combination with radiation therapy in treating patients with diffuse midline gliomas that is newly diagnosed or has come back (recurrent) or other…
- Conditions
- Diffuse Midline Glioma (DMG), Glioblastoma, Recurrent Ependymoma, Recurrent Malignant Central Nervous System Neoplasm
- Trial name
- PNOC023 (NCT04732065)
- Testing
- ONC206, Standard of Care Radiation Therapy, Optional Proton (1H) MR spectroscopy (MRS)
- Where
- 7 sites in United States, Netherlands and 1 more
- Volunteers
- 208 people
- Sponsor
- Sabine Mueller, MD, PhD
Glioblastoma, High-grade Glioma
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
A greater extent of resection of the contrast-enhancing (CE) tumor part has been associated with improved outcomes in high-grade glioma patients.
- Conditions
- Glioblastoma, High-grade Glioma, Glioblastoma, IDH-wildtype, Glioblastoma, IDH-mutant
- Trial name
- SUPRAMAX (NCT06118723)
- Testing
- Supramaximal resection, Maximal safe resection
- Where
- 8 sites in United States, Belgium and 3 more
- Volunteers
- 784 people
- Sponsor
- Jasper Gerritsen
Brain Tumor, Primary, Meningioma
SeOuL cOhort of Brain Tumor MONitoring Study (SOLOMON)
The registry of this study was subjected to patients who were radiologically diagnosed with a non-malignant brain tumor at Seoul National University Hospital since 2001, and who have had magnetic resonance (MR) re-examination…
- Conditions
- Brain Tumor, Primary, Meningioma, Schwannoma, Pituitary Adenoma
- Trial name
- SOLOMON (NCT05254197)
- Where
- South Korea
- Volunteers
- 3,000 people
- Sponsor
- Seoul National University Hospital
Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma)
5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
The purpose of this clinical trial is to evaluate the safety and tolerability of avutometinib and defactinib and to determine the preliminary antitumour activity of avutometinib and defactinib administered at the recommended…
- Conditions
- Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma), Diffuse Hemispheric Glioma, H3 G34-Mutant, Malignant Primary Gliomas
- Trial name
- 5G-RUBY (NCT06630260)
- Testing
- Avutometinib, Defactinib, Temozolomide
- Where
- 3 sites in United Kingdom
- Volunteers
- 182 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Malignant Primary Gliomas, Glioblastoma Multiforme (GBM)
5G-PEARL: Paxalisib in Malignant Brain Tumours
The purpose of this clinical trial is to evaluate the safety and tolerability of paxalisib in combination with temozolomide and to determine the preliminary antitumour activity of the combination therapy.
- Trial name
- 5G-PEARL (NCT07391215)
- Testing
- Paxalisib, Temozolomide capsule
- Where
- United Kingdom
- Volunteers
- 64 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Diffuse Midline Glioma, H3 K27-Altered, Metastatic Malignant Neoplasm in the Central Nervous System
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does…
- Conditions
- Diffuse Midline Glioma, H3 K27-Altered, Metastatic Malignant Neoplasm in the Central Nervous System, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Diffuse Midline Glioma, H3 K27-Altered
- Trial name
- NCT04870944
- Testing
- Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy
- Where
- 35 sites in United States, Australia
- Volunteers
- 63 people
- Sponsor
- Children's Oncology Group
Primary Malignant Brain Tumors
A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Diffuse Glioma
Glioma is a major histological subtype of primary malignant brain tumors in Taiwan, with distinct epidemiological, clinical, and pathological features comparing to the other common cancer diseases.
- Trial name
- NCT05622409
- Where
- 8 sites in Taiwan
- Volunteers
- 250 people
- Sponsor
- National Health Research Institutes, Taiwan
High Grade Glioma, Meningioma
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
This study will evaluate the safety and efficacy of Lutathera (177Lu-DOTATATE) in patients with progressive or recurrent High-Grade Central Nervous System (CNS) tumors and meningiomas that demonstrate uptake on DOTATATE PET.
- Conditions
- High Grade Glioma, Meningioma, Embryonal Tumor, Medulloblastoma
- Trial name
- NCT05278208
- Testing
- LUTATHERA® (Lutetium Lu 177 dotatate)
- Where
- 4 sites in United States
- Volunteers
- 65 people
- Sponsor
- Nationwide Children's Hospital